Research & Clinical Trials

Research & Clinical Trials

Raffles Cancer Centre actively seeks partnerships with research organisations who share our passion in our mission to provide the best cancer care for our patients.

Clinical trials constitute an integral component of patient management at Raffles Hospital. Through these trials, our patients have access to novel therapeutic agents, which have yet to be made available in the market. These clinical trials give hope to patients whose conditions have failed to respond to standard lines of treatment.

Our oncologists and haematologists at Raffles Cancer Centre have abundant experience as principal investigators and co-investigators of well over 50 clinical trials in various phases (phase I, II, III), both investigator-initiated and pharmaceutical company-initiated, and as part of larger international multi-centre phase III trials.

Coordinated by the Hospital‘s Clinical Trial Unit, these trials help expand the treatment options available to patients.

All clinical trials involving humans are subjected to approval by the Hospital’s Institutional Review Board (IRB) which ensures all clinical trials are ethically acceptable and that the rights, safety and well-being of the patients are safeguarded at all times. The IRB also monitors the conduct of the clinical trials and ensures that they are in compliance with Good Clinical Practice on an ongoing basis.

No.IndicationStudy Information InvestigatorStatus
1Lung CancerA Phase II, Open-label, Single-arm, Multi-centre Study to Evaluate the Safety and Efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (OSTARA)Dr Terence TanRecruiting
2Lung CancerA Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non?Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (STAR-121)Dr Terence TanRecruiting
3Breast CancerA Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2 Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)Dr Terence TanRecruiting
4Breast CancerA Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician?s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1Dr Terence TanRecruiting
5Breast CancerA Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician?s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1Dr Terence TanRecruiting
6StrokeA Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of MLC1501 in Patients with StrokeDr RamaniRecruiting
7Gastric CancerA Pilot Study of Natural Killer Group 2D (NKG2D) Ligand Expression in Cancer Cells of Patients with Advanced Gastric Cancer and Susceptibility to Cancer Cell Killing by Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted ?‰ T Cells In Vitro.Dr Terence TanRecruiting

For more information, please contact:

Raffles Hospital Clinical Trials Unit

Mon - Fri: 9.00am to 5.00pm
Tel: +65 6311 2305

Make an enquiry

Your participation in this research study is purely voluntary. You may withdraw your participation at any phase during the study.

Updated on ​​Dec 2023

Contact Raffles Cancer Centre

Make an enquiry if you require more information.

Our staff will get back to you within 2 working days.